Effects Of Different Temperature Of Moxibustion On Lipid Level In A Mice Model Of Hyperlipidemia And The Relationship With TRPV1

Objective:To observe the effect of different temperature moxibustion in mouse model of hyperlipidemia and moxibustion local skin tissue, confirming the efficacy of moxibustion in controlling inflammation and decreasing lipid, and exploring the possible mechanism of it.Methods:Forty C57BL/6J mice (two-month-old) were randomly divided into normal control group, model control group,38℃ moxibustion group,45℃ moxibustion group, ten in each group. Except the normal control group, the other three groups high fat diet six weeks cause hyperlipidemia model.38℃ moxibustion group and 45℃ moxibustion group are using different temperature moxibustion on RN08,10minutes for one time, every other day at a time, monitored by temperature controller. Draw materials immediately after two weeks of treatment, then detect TC、TG、TRPV1、TLR4、NF-κB and observe the changes of skin structure with HE staining and toluidine blue staining.Results:1.38℃ moxibustion group,45℃ moxibustion group TC and TG levels decreased significantly (P<0.05) compared with the model group.45℃ moxibustion group reducing TC, TG’s trend is better than 38℃ moxibustion group (P<0.05).2.45℃ moxibustion group TLR4 and NF-kB levels decreased significantly (P<0.05) compared with the model group.38℃ moxibustion group TLR4 and NF-kB levels decreased unsignificantly (P> 0.05).3.45℃ moxibustion group TRPV1 levels increased significantly (P<0.05) and 38℃ moxibustion group TRPV1 content did not change (P> 0.05) compared with the model group.4. local multi-layered skin tissue of 45℃ moxibustion group changed and mast cell degranulation occurred.Conclusion:1.moxibustion have a good regulation on mouse model of hyperlipidemia. 2.45℃ moxibustion group have good lipid-lowering effect than 38℃ moxibustion group. 3.45℃ moxibustion group can decrease lipid and control inflammation.it is related to activation of TRPV1.4The activation of TRPV1 may be associated with TLR-NF-kB signaling pathway.